Investor News no. 3/2007
To OMX Nordic Exchange Copenhagen Copenhagen, November 27, 2007
Investor News: Curalogic has presented at the Piper Jaffray Conference in New
York
Curalogic A/S (OMX: CUR) participates in Piper Jaffray 19th Annual Healthcare
Conference November 27-29, 2007 in New York.
The presentation was held by Peter Moldt, Ph.D., President and Chief Executive
Officer of Curalogic and was scheduled for:
Tuesday 8:30 AM local time on November 27, 2007.
The PowerPoint presentation is available at www.curalogic.com.
Yours sincerely
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO Tel +45 99 99 24 00, mobile +45 2625 0422
Helle Busck Fensvig, EVP and CFO Tel +45 99 99 24 00, mobile +45 2070 5537
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic
Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the
treatment of allergy. By combining the best of two worlds - the efficacy of
immunotherapy combined with the safety and patient convenience of symptomatic
treatments - Curalogic aims to develop a novel and user-friendly form of allergy
treatment, and make it the preferred type of allergy treatment among patients.
Curalogic has a broad and mature pipeline with a product for treatment of
ragweed allergy in Phase III, a product for treatment of grass allergy ready for
Phase III, a product for treatment of cat allergy in Phase II and a product for
treatment of house dust mite allergy preparing for clinical trials.
